Literature DB >> 36274066

Metabolic control of CD47 expression through LAT2-mediated amino acid uptake promotes tumor immune evasion.

Zenan Wang1,2,3, Binghao Li1,2,3, Shan Li4, Wenlong Lin1,5, Zhan Wang1,2,3, Shengdong Wang1,2,3, Weida Chen1, Wei Shi1, Tao Chen1,2,3, Hao Zhou1,2,3, Eloy Yinwang1,2,3, Wenkan Zhang1,2,3, Haochen Mou1,2,3, Xupeng Chai1,2,3, Jiahao Zhang1,2,3, Zhimin Lu4,6, Zhaoming Ye7,8,9.   

Abstract

Chemotherapy elicits tumor immune evasion with poorly characterized mechanisms. Here, we demonstrate that chemotherapy markedly enhances the expression levels of CD47 in osteosarcoma tissues, which are positively associated with patient mortality. We reveal that macrophages in response to chemotherapy secrete interleukin-18, which in turn upregulates expression of L-amino acid transporter 2 (LAT2) in tumor cells for substantially enhanced uptakes of leucine and glutamine, two potent stimulators of mTORC1. The increased levels of leucine and enhanced glutaminolysis activate mTORC1 and subsequent c-Myc-mediated transcription of CD47. Depletion of LAT2 or treatment of tumor cells with a LAT inhibitor downregulates CD47 with enhanced macrophage infiltration and phagocytosis of tumor cells, and sensitizes osteosarcoma to doxorubicin treatment in mice. These findings unveil a mutual regulation between macrophage and tumor cells that plays a critical role in tumor immune evasion and underscore the potential to intervene with the LAT2-mediated amino acid uptake for improving cancer therapies.
© 2022. The Author(s).

Entities:  

Year:  2022        PMID: 36274066     DOI: 10.1038/s41467-022-34064-4

Source DB:  PubMed          Journal:  Nat Commun        ISSN: 2041-1723            Impact factor:   17.694


  52 in total

1.  Chemotherapy induces enrichment of CD47+/CD73+/PDL1+ immune evasive triple-negative breast cancer cells.

Authors:  Debangshu Samanta; Youngrok Park; Xuhao Ni; Huili Li; Cynthia A Zahnow; Edward Gabrielson; Fan Pan; Gregg L Semenza
Journal:  Proc Natl Acad Sci U S A       Date:  2018-01-24       Impact factor: 11.205

Review 2.  Natural innate and adaptive immunity to cancer.

Authors:  Matthew D Vesely; Michael H Kershaw; Robert D Schreiber; Mark J Smyth
Journal:  Annu Rev Immunol       Date:  2011       Impact factor: 28.527

Review 3.  Innate and adaptive immune cells in the tumor microenvironment.

Authors:  Thomas F Gajewski; Hans Schreiber; Yang-Xin Fu
Journal:  Nat Immunol       Date:  2013-10       Impact factor: 25.606

Review 4.  Translational biology of osteosarcoma.

Authors:  Maya Kansara; Michele W Teng; Mark J Smyth; David M Thomas
Journal:  Nat Rev Cancer       Date:  2014-10-16       Impact factor: 60.716

5.  Chemopreventive agents induce programmed death-1-ligand 1 (PD-L1) surface expression in breast cancer cells and promote PD-L1-mediated T cell apoptosis.

Authors:  Ping Zhang; Dong-Ming Su; Mei Liang; Jian Fu
Journal:  Mol Immunol       Date:  2007-10-24       Impact factor: 4.407

Review 6.  Osteosarcoma: Current Treatment and a Collaborative Pathway to Success.

Authors:  Michael S Isakoff; Stefan S Bielack; Paul Meltzer; Richard Gorlick
Journal:  J Clin Oncol       Date:  2015-08-24       Impact factor: 44.544

Review 7.  Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer.

Authors:  L Bracci; G Schiavoni; A Sistigu; F Belardelli
Journal:  Cell Death Differ       Date:  2013-06-21       Impact factor: 15.828

Review 8.  Targeting autophagy is a promising therapeutic strategy to overcome chemoresistance and reduce metastasis in osteosarcoma.

Authors:  Yu-Xin Liao; Hai-Yang Yu; Ji-Yang Lv; Yan-Rong Cai; Fei Liu; Zhi-Min He; Shi-Sheng He
Journal:  Int J Oncol       Date:  2019-10-18       Impact factor: 5.650

9.  Single-cell RNA landscape of intratumoral heterogeneity and immunosuppressive microenvironment in advanced osteosarcoma.

Authors:  Yan Zhou; Dong Yang; Qingcheng Yang; Xiaobin Lv; Wentao Huang; Zhenhua Zhou; Yaling Wang; Zhichang Zhang; Ting Yuan; Xiaomin Ding; Lina Tang; Jianjun Zhang; Junyi Yin; Yujing Huang; Wenxi Yu; Yonggang Wang; Chenliang Zhou; Yang Su; Aina He; Yuanjue Sun; Zan Shen; Binzhi Qian; Wei Meng; Jia Fei; Yang Yao; Xinghua Pan; Peizhan Chen; Haiyan Hu
Journal:  Nat Commun       Date:  2020-12-10       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.